Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2017369 | 0.87 | KMT2A (0.71) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL2020438 | 0.87 | KMT2A (0.71) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL20138823 | 0.87 | KMT2A (0.51) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL3061001 | 0.86 | KMT2A (0.50) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL2021172 | 0.86 | KMT2A (0.70) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL437697 | 0.85 | KMT2A (0.68) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL6289957 | 0.85 | KMT2A (0.68) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL2719292 | 0.85 | KMT2A (0.68) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL11244456 | 0.85 | MEN1 (0.68) | KMT2AMEN1MAPTLMNAHTT | |
| SCHEMBL6537339 | 0.85 | KMT2A (0.68) | KMT2AMEN1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559481-B2 | Quinoline derivatives | ELANCO ANIMAL HEALTH GMBH (DE) | 2026-02-24 | — | — | US | disclosed |
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | ELANCO TIERGESUNDHEIT AG (CH) | 2025-10-21 | — | — | US | disclosed |
| EP-3634959-B1 | QUINOLINE DERIVATIVES FOR TREATING INFECTIONS WITH HELMINTHS | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-02-26 | — | — | EP | disclosed |
| CN-114206860-B | Bicyclic derivatives for the treatment of endoparasites | 礼蓝动物保健有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240360116-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (SZ) | 2024-10-31 | — | — | US | disclosed |
| CN-112074514-B | Quinoline derivatives | 礼蓝动物保健有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-111132977-B | Quinoline derivatives for the treatment of helminth infections | 礼蓝动物保健有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-116888124-A | Bicyclic derivatives | 礼蓝动物保健有限公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-4255911-A1 | BICYCLIC DERIVATIVES | Elanco Tiergesundheit AG (CH) | 2023-10-11 | — | — | EP | disclosed |
| US-20230141809-A1 | QUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-05-11 | — | — | US | disclosed |
| US-20020132826-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | WYETH HOLDINGS CORPORATION | 2002-09-19 | — | — | US | disclosed |
| CN-1337962-A | Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors | AMERICAN CYANAMID CO (US) | 2002-02-27 | — | — | CN | disclosed |
| US-20010046989-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | WYETH HOLDINGS CORPORATION | 2001-11-29 | — | — | US | disclosed |
| EP-1157024-A1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | American Cyanamid Company (US) | 2001-11-28 | — | — | EP | disclosed |
| US-20010025047-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | WYETH HOLDINGS CORPORATION | 2001-09-27 | — | — | US | disclosed |
| US-6228869-B1 | ANTITUMOR, ANTIMETASTASIS, ANTIARTHRITIC, AND WOUND HEALING AGENTS; QUINOLINE AND ISOQUINOLINE DERIVATIVES | AMERICAN CYANAMID COMPANY | 2001-05-08 | — | — | US | disclosed |
| CN-1280568-A | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | AMERICAN CYANAMID CO (US) | 2001-01-17 | — | — | CN | disclosed |
| WO-2000044749-A1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-1021413-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | American Cyanamid Company (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999018076-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | TBXA2R, PIGS, CYCS | KMT2A 2765/4885MEN1 2037/4885NPC1 2984/4885 |
| US-20240360116-A1 | BICYCLIC DERIVATIVES | FABP3, CYCS, TNNI3 | KMT2A 2925/4885MEN1 2797/4885NPC1 3005/4885 |
| US-20020132826-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | MSR1, TIMP3, OGFR | KMT2A 3640/4885MEN1 4416/4885NPC1 621/4885 |
| US-20230141809-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, QTRT2 | KMT2A 1122/4885MEN1 654/4885NPC1 850/4885 |
| US-12559481-B2 | Quinoline derivatives | HRH1, HRH2, HRH4 | KMT2A 2587/4885MEN1 1315/4885NPC1 202/4885 |
| US-20010025047-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | MSR1, TIMP3, TGFBR2 | KMT2A 3333/4885MEN1 4366/4885NPC1 824/4885 |
| US-20010046989-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | MSR1, TIMP3, TGFBR2 | KMT2A 3415/4885MEN1 4394/4885NPC1 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.